Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule

Francesco D'Alo', Stefan Hohaus, Livio Pagano, Maria Teresa Voso, Luana Fianchi, Marianna Criscuolo, Marco Greco, Giuseppe Leone

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

3 Citazioni (Scopus)

Abstract

no abstract
Lingua originaleEnglish
pagine (da-a)e15-e15-7
RivistaLeukemia Research
Volume36
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • Aged
  • Antimetabolites, Antineoplastic
  • Azacitidine
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Approval
  • Humans
  • Male
  • Myelodysplastic Syndromes
  • Time Factors

Fingerprint Entra nei temi di ricerca di 'Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule'. Insieme formano una fingerprint unica.

Cita questo